EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

The impact of semaglutide on wound healing in diabetes related foot ulcer patients: A TriNetX database study

Joshua E Lewis iD, Diana K Omenge iD, Amani R Patterson iD, Ogechukwu Anwaegbu iD, Nangah N Tabukum, Jimmie E Lewis, Wei-Chen Lee

Diabetes & Vascular Disease Research · 2025-03 · 22 (2)

DOI: 10.1177/14791641251322909 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Diabetes & Vascular Disease Research, online erschienen am 13.03.2025. Verfasst von Joshua E Lewis und 6 weiteren Autor:innen. Beteiligte Einrichtung: John Sealy School of Medicine, University of Texas Medical Branch, Galveston, TX, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Wound Healing, Diabetic Foot, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCATS NIH HHS, HRSA HHS, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Diabetes related foot ulcers (DFUs) are common complications of type 2 diabetes mellitus (T2DM), affecting 15–25% of individuals living with diabetes and significantly contributing to healthcare costs ($9–13 billion annually in the U.S.). Without effective management, these wounds often lead to severe outcomes like amputations. This study aims to examine the association of semaglutide on DFU management.

Methods

This retrospective cohort study utilized TriNetX US Research Network data to assess the impact of semaglutide, a GLP-1 receptor agonist, on DFU outcomes between 2013 and 2023. The study compared outcomes between semaglutide users with DFU (Cohort A, N = 6329) and non-users with DFU (Cohort B, N = 118,821) across 64 healthcare organizations. We matched participants by age, gender, race, and ethnicity; however, we excluded patients with certain co-morbidities. Statistical analysis, such as chi-square analysis and risk ratio, using TriNetX software evaluated different complication outcomes.

Results

Semaglutide users with DFU demonstrated lower relative risks for complications compared to non-users. Within 1 year, semaglutide users were associated with lower relative risks for wound healing complications (0.19% vs 0.38%), chronic non-healing wounds (0.75% vs 1.23%), chronic pain (4.44% vs 8.06%), wound care (2.42% vs 4.86%), wound dehiscence (0.26% vs 0.56%), and amputation (2.34% vs 5.21%) ( p < .05). Similar trends persisted over 5 years. While these findings highlight potential benefits of semaglutide with patients with DFU, causation cannot be inferred due to the study’s observational design.

Conclusion

Semaglutide use was associated with favorable outcomes in patients with diabetes-related foot ulcers, including reductions in wound-related complications. While these findings suggest potential benefits of semaglutide as an adjunct in DFU management, further research is needed to confirm these associations and to better understand the mechanisms involved.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like PeptidesWound HealingDiabetic FootDiabetes Mellitus, Type 2Hypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsHumansFemaleMaleRetrospective StudiesMiddle AgedTreatment OutcomeAgedDatabases, FactualTime FactorsUnited StatesRisk FactorsRisk AssessmentAmputation, SurgicalGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

Diabetes related foot ulcersGLP-1 receptor agonistsdiabetes complicationssemaglutidewound healing

Substanzen

Glucagon-Like PeptidesHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • John Sealy School of Medicine, University of Texas Medical Branch, Galveston, TX, USA.
  • Tilman J. Fertitta College of Medicine, University of Houston School of Medicine, Houston, TX, USA.
  • School of Podiatric Medicine, Barry University, Miami, FL, USA.
  • Department of Family Medicine, University of Texas Medical Branch, Galveston, TX, USA.

ORCID-Profile: Joshua E Lewis, Diana K Omenge, Amani R Patterson, Ogechukwu Anwaegbu

Förderung

  • NCATS NIH HHS
  • HRSA HHS
  • National Center for Advancing Translational Sciences
  • Department of Health and Human Services, Health Resources and Services Administration

Zitieren

APA

Lewis, J. E., Omenge, D. K., Patterson, A. R., Anwaegbu, O., Tabukum, N. N., Lewis, J. E., & Lee, W. C. (2025). The impact of semaglutide on wound healing in diabetes related foot ulcer patients: A TriNetX database study. Diabetes & Vascular Disease Research, 22(2). https://doi.org/10.1177/14791641251322909

Vancouver

Lewis JE, Omenge DK, Patterson AR, Anwaegbu O, Tabukum NN, Lewis JE, et al. The impact of semaglutide on wound healing in diabetes related foot ulcer patients: A TriNetX database study. Diabetes & Vascular Disease Research. 2025;22(2). doi:10.1177/14791641251322909

BibTeX
@article{Lewis2025,
  author = {Lewis, Joshua E and Omenge, Diana K and Patterson, Amani R and Anwaegbu, Ogechukwu and Tabukum, Nangah N and Lewis, Jimmie E and Lee, Wei-Chen},
  title = {The impact of semaglutide on wound healing in diabetes related foot ulcer patients: A TriNetX database study},
  journal = {Diabetes & Vascular Disease Research},
  year = {2025},
  volume = {22},
  number = {2},
  doi = {10.1177/14791641251322909}
}
Kostenlos starten →